DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma ...Middle East

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations...

Read More Details
Finally We wish PressBee provided you with enough information of ( DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma )

Also on site :

• Disney World Announces Opening Date for First Nighttime Parade in Nearly a Decade
• 'Law & Order' Fans Stunned by 'Girls Night Out' Photos of Mariska Hargitay and Kelli Giddish
• Mama June Shannon Quit Weight Loss Shots Cold Turkey—Here’s Why